Penn Medicine Provider
Neurology
Chafic Karam, MD
4.9
(157)
Accepting new patients
Sees patients age 18 and up
Penn Neuroscience Center - Neurology
Make an appointmentCall 800-789-7366

About me

  • Professor of Clinical Neurology

Education and training

  • Medical School: Saint Joseph's University Medical School
  • Residency: Hotel Dieu de France
  • Residency: Mount Sinai Beth Israel
  • Residency: Massachusetts General Hospital/Brigham and Women’s Hospital
  • Residency: Mayo Clinic

What my patients think about me

Average Rating
4.9

159 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

April 2025
5.0
5.0
great overall
April 2025
5.0
5.0
good communication
April 2025
5.0
5.0
good visit. great neurologist.
March 2025
5.0
5.0
timely quality services!

Insurance accepted

My Locations

Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Karam is a Penn Medicine physician.

Qualifications and experience

My research

Hsu RT, Wilson J, Karam C. Amyloid Spikes on Optical Coherence Tomography Demonstrating Ocular Involvement in ATTRv Amyloidosis , Neurology. : 2025

Bril V, Drużdż A, Grosskreutz J, Habib AA, Kaminski HJ, Mantegazza R, Sacconi S, Utsugisawa K, Vu T, Boehnlein M, Gayfieva M, Greve B, Woltering F, Vissing J; MG0004 study investigators. Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. , J Neurol.: 2025

Morganroth J, Karam C. Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments , Neurol Clin Pract. : 2025

Rebello, S., Hsu, K., Nativi-Nicolau, J., Karam, C., Grogan, M., Lousada, I., & Maurer, M. S. Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey. , Amyloid, 1–10: 2025

Qarni TN, Jones FJS, Drachman B, Khella S, Pieretti J, Bustamante NS, Karam C. Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study , Orphanet J Rare Dis.: 2024

Karam C. Navigating the switch from IVIG to FcRn inhibition in CIDP: Clinical insights. J Neurol Sci. 2024 Dec 16;468:123354 , J Neurol Sci., 468(123354): 2024

Bhatt K, Delgado DH, Khella S, Bumma N, Karam C, Keller A, Rosen AM, Bozas A, Shea A, Towne MC, Polfus LM, Kaeser GE, Sanjurjo V, Shah KB. Hereditary Transthyretin Amyloidosis in Patients Referred to a Genetic Testing Program. , J Am Heart Assoc. 2024 Nov 22:e033770.: 2024

Karam C, Moffit C, Summers C, Merkel MP, Kochman FM, Weijers L, Puls M, Schurer M, Jones E, Mason N, Finkel M, Schmitt P, Hanna M. The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement. , Orphanet J Rare Dis.: 2024

Jones FJS, Zager E, Karam C. Clinical Reasoning: A 61-Year-Old Man With Progressive Right Leg Numbness and Weakness. , Neurology. 2024 Oct 22;103(8):e209900: 2024

Suhr, O. B., Grogan, M., Silva, A. M. da, Karam, C., Garcia-Pavia, P., Drachman, B., … Kinney, G. G. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. , Amyloid. 2024 Oct 29:1-8. : 2024

View all publications